Related Experiment Videos
Postmenopausal hormone therapy and lung cancer
1Department of Medicine 'T', Ichilov Hospital, Tel-Aviv, Israel.
Climacteric : the Journal of the International Menopause Society
|October 19, 2010
Summary
Postmenopausal hormone therapy (HT) requires careful benefit-risk assessment. Combined estrogen + progestin (E+P) HT may increase lung cancer mortality, but risks are minimal for younger women and short-term users.
Area of Science:
- Oncology
- Endocrinology
- Women's Health
Background:
- Current postmenopausal hormone therapy (HT) guidelines emphasize individualized benefit-risk evaluation.
- Lung cancer has been identified as a potential serious adverse effect of HT.
Purpose of the Study:
- To analyze the association between hormone therapy (HT) and lung cancer, particularly focusing on mortality risks.
- To differentiate risks associated with estrogen-only versus combined estrogen + progestin (E+P) regimens.
Main Methods:
- Review of recent studies investigating the link between HT and lung cancer.
- Analysis of mortality data in lung cancer patients undergoing HT.
Main Results:
- Estrogen-alone therapy does not appear to carry a risk for lung cancer.
- Combined estrogen + progestin (E+P) therapy may be linked to increased lung cancer mortality.
- No increased risk observed in E+P users aged 50-59 or those using HT for less than 5 years.
- Absolute risk increase is less than one additional lung cancer case per 1000 woman-years of HT use.
Conclusions:
- The decision to use HT should be based on a thorough assessment of individual benefits and risks.
- Combined E+P therapy warrants caution due to potential increased lung cancer mortality, especially for long-term use or older age groups.
- The absolute increase in lung cancer risk associated with HT is very low.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...